tiprankstipranks
Nanobiotix Advances in Cancer Treatment Study
Company Announcements

Nanobiotix Advances in Cancer Treatment Study

Nanobiotix (NBTX) has released an update.

Pick the best stocks and maximize your portfolio:

Nanobiotix has successfully completed a Phase 1 study of its promising cancer treatment, NBTXR3, showing improved survival rates in pancreatic cancer patients. The study’s favorable outcomes have led to US FDA approval for a new cohort to further explore the treatment’s potential in combination with standard chemotherapy. With ongoing recruitment, the company is poised to present comprehensive results in early 2025, marking a significant step for investors interested in innovative cancer therapies.

For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNanobiotix Executive Acquires Significant Share Volume, Signaling Confidence in Future Growth
TipRanks Auto-Generated NewsdeskNanobiotix Updates Share Capital and Voting Rights Information
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App